Adoptive Transfer of iTregs for FVIII Tolerance
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization : Versiti Blood Center of Wisconsin
Variable analysis
- Adoptive transfer of one million pltLys-iTreg or purTGFβ-iTreg cells by IV injection into F8null/B6 mice
- Weekly rhF8 (Xyntha; Pfizer Inc., New York, NY) immunization at 50 U/kg per week IV for a total of 4 weeks
- Titers of anti-FVIII inhibitory antibodies (inhibitors) determined by Bethesda assay
- Titers of total anti-FVIII antibodies determined by enzyme-linked immunosorbent assay (ELISA)
- Recovery of the infused iTregs assessed by flow cytometry for enhanced green fluorescent protein (EGFP) expression in CD4+ T cells from peripheral blood
- F8null/B6 mouse strain
- CD45.1 and CD45.2 congenic markers used to identify the infused iTregs
- Positive control: Not explicitly mentioned
- Negative control: Not explicitly mentioned
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!